A qui­et car­dio up­start makes some noise, get­ting $300M from Bain and div­ing deep in­to the clin­ic — with some re­al mon­ey for pipeline deals

The small ex­ec­u­tive team at Car­du­ri­on has been stick­ing care­ful­ly to its goals, in-li­cens­ing a lead car­dio drug from Astel­las in 2018 and mak­ing a care­ful trek in­to hu­man stud­ies as they ad­vanced a fol­low-up pro­gram and grad­u­al­ly built out an­oth­er pre­clin­i­cal prospect.

In­volved in one of the most grind­ing­ly tough fields in drug R&D, they nev­er thought much of tout­ing their work. They did deals with Take­da and Pfiz­er with­out mak­ing much of a show of it. Even es­tab­lished a small op­er­at­ing unit in Japan. Po­laris in­vest­ed, but no one ever said how much — or much about why.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER